4.7 Article

Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder

Journal

JOURNAL OF NEUROSCIENCE
Volume 41, Issue 5, Pages 901-910

Publisher

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.1647-20.2020

Keywords

anxiety; angiotensin II; oxytocin; PTSD; tachykinin; vasopressin

Categories

Funding

  1. National Institutes of Health [1R01HL137103-01A1, 3R01HL137103-02S1, R01MH113007, R01MH113007-04S1, R00MH108734]
  2. Veterans Administration Advanced Research Fellowship
  3. Intramural Research Program, National Institute of Mental Health [ZIAMH002798]
  4. Sloan Research Fellowship
  5. Klingenstein-Simons Fellowship
  6. National Alliance for Research on Schizophrenia and Depression Young Investigator Grant [22434]
  7. Ramon y Cajal program [RYC2014-15784]
  8. RETOS-MINECO [SAF2016-76565-R FEDER]
  9. ERANET-Neuron JTC [2019 ISCIII AC19/00077]

Ask authors/readers for more resources

Post-traumatic stress disorder (PTSD) is associated with dysregulation of limbic neuropeptides, with studies showing that blocking certain pathways can weaken fear memory consolidation, enhance fear extinction, and improve threat discrimination. Novel approaches targeting these pathways offer promising potential for treating core elements of PTSD pathophysiology.
Post-traumatic stress disorder (PTSD) is characterized by hypervigilance, increased reactivity to unpredictable versus predictable threat signals, deficits in fear extinction, and an inability to discriminate between threat and safety. First-line pharmacotherapies for psychiatric disorders have limited therapeutic efficacy in PTSD. However, recent studies have advanced our understanding of the roles of several limbic neuropeptides in the regulation of defensive behaviors and in the neural processes that are disrupted in PTSD. For example, preclinical studies have shown that blockers of tachykinin pathways, such as the Tac2 pathway, attenuate fear memory consolidation in mice and thus might have unique potential as early post-trauma interventions to prevent PTSD development. Targeting this pathway might also be beneficial in regulating other symptoms of PTSD, including trauma-induced aggressive behavior. In addition, preclinical and clinical studies have shown the important role of angiotensin receptors in fear extinction and the promise of using angiotensin II receptor blockade to reduce PTSD symptom severity. Additional preclinical studies have demonstrated that the oxytocin receptors foster accurate fear discrimination by facilitating fear responses to predictable versus unpredictable threats. Complementary human imaging studies demonstrate unique neural targets of intranasal oxytocin and compare its efficacy with well-established anxiolytic treatments. Finally, promising data from human subjects have demonstrated that a selective vasopressin 1A receptor antagonist reduces anxiety induced by unpredictable threats. This review highlights these novel promising targets for the treatment of unique core elements of PTSD pathophysiology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available